Insider Selling: Oncology Institute (NASDAQ:TOI) Director Sells 50,000 Shares of Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Mark Pacala sold 50,000 shares of Oncology Institute stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $4.00, for a total transaction of $200,000.00. Following the sale, the director directly owned 174,971 shares of the company’s stock, valued at $699,884. The trade was a 22.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Oncology Institute Stock Performance

Oncology Institute stock traded down $0.03 during trading hours on Thursday, hitting $3.24. The company had a trading volume of 4,864,210 shares, compared to its average volume of 1,672,667. The firm has a 50-day moving average of $3.78 and a 200 day moving average of $3.35. The company has a debt-to-equity ratio of 14.58, a current ratio of 1.68 and a quick ratio of 1.39. The firm has a market cap of $302.96 million, a PE ratio of -5.06 and a beta of 0.07. The Oncology Institute, Inc. has a one year low of $0.13 and a one year high of $4.88.

Oncology Institute (NASDAQ:TOI) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The firm had revenue of $136.56 million for the quarter, compared to the consensus estimate of $122.63 million. Oncology Institute had a negative return on equity of 1,527.21% and a negative net margin of 13.21%. Oncology Institute has set its FY 2025 guidance at EPS.

Wall Street Analysts Forecast Growth

TOI has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a report on Wednesday, October 8th. Noble Financial initiated coverage on shares of Oncology Institute in a research note on Wednesday, July 23rd. They issued an “outperform” rating and a $8.00 price target on the stock. Finally, BTIG Research reaffirmed a “buy” rating and set a $7.00 price target on shares of Oncology Institute in a research report on Tuesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Hedge Funds Weigh In On Oncology Institute

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Josh Arnold Investment Consultant LLC acquired a new stake in shares of Oncology Institute during the 1st quarter worth $2,267,000. CenterBook Partners LP lifted its position in Oncology Institute by 277.8% during the third quarter. CenterBook Partners LP now owns 2,704,650 shares of the company’s stock worth $9,439,000 after purchasing an additional 1,988,751 shares during the period. Kanen Wealth Management LLC bought a new stake in Oncology Institute during the third quarter worth about $6,421,000. Marshall Wace LLP acquired a new stake in Oncology Institute during the second quarter worth about $3,028,000. Finally, Geode Capital Management LLC increased its holdings in Oncology Institute by 231.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company’s stock valued at $2,623,000 after buying an additional 893,696 shares during the period. 36.86% of the stock is owned by institutional investors and hedge funds.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.